KRISNA BHARGAVA, PHD
Co-inventor of ReoLab's core technology. Expertise in sensor design, microfluidics, and additive manufacturing. Postdoctoral Scholar at USC Viterbi School of Engineering.
NOAH MALMSTADT, PHD
Co-inventor of ReoLab's core technology. Recognized expert in microfluidics, soft matter physics, and molecular biophysics. Associate Professor of Chemical Engineering, Materials Science, and Biomedical Engineering at USC Viterbi School of Engineering.
Angel investor, board member, and strategic advisor to several hardware, software, and life science companies.
MITCHELL GROSS, MD/PHD
Expert in circulatory biomarkers, oncology, an urology. Research Director of the Norris Westside Cancer Center and the Center of Applied Molecular Medicine at USC. Associate Professor of Clinical Medicine at USC Keck School of Medicine.
RICHARD BACHUR, MD
Nationally recognized clinical expert in pediatric emergency medicine. Research focus on diagnostic approaches for common pediatric infectious diseases. Chief of Emergency Medicine at Boston Children’s Hospital. Professor of Pediatrics and Emergency Medicine at Harvard Medical School.
KULJEET RAI, MD
Seasoned Family Practitioner, Concierge doctor, and PI for infectious disease clinical trials. President of Rai Research Associates. Adjunct Associate Professor of Medicine at Stanford Medical School and USC Keck School of Medicine.
RICHARD ROBERTS, PHD
Early pioneer in microfluidics and a leading expert in biomolecular engineering. Chair of the Chemical Engineering and Materials Science department at USC Viterbi School of Engineering. Professor of Chemistry, Chemical Engineering, and Biology at USC. Full member of the USC Norris Westside Cancer Center.
ReoLab is currently located in Berkeley, California.
Interested in learning more? Contact us using the form below:
PRECISION TESTING AT THE POINT-OF-CARE.
Today, caregivers primarily rely on their clinical skills and patient self-reporting to assess whether or not to admit a patient for further testing, prescribe antibiotics, or discharge a patient from the hospital. Difficulty differentiating bacterial causes of acute respiratory symptoms results in 47M excess antibiotic prescriptions a year, driving $7B in adverse drug reaction costs and the evolution of multi-drug resistant "superbugs". Vigilant use of quantitative immunoassays during diagnosis has been shown to greatly decrease overprescription rates and overtesting of patients, but they are often too slow and inaccessible for time-sensitive environments like primary care and the ER.
ReoLab technology can do any central lab quantitative immunoassay in less than an hour, on the benchtop. We can empower caregivers with the information they need to make clear treatment decisions, as they need it.
Bacterial respiratory infections are a leading killer of young children and the elderly. Their early symptoms are often similar to those of more benign viral infections or allergic responses.
Our mission is to provide caregivers with rapid, objective guidance in treating these cases.